UNSPSC 51283914: Sulfaguanidine

This classification denotes a sulfonamide anti-infective agent with the molecular formula C7H10N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15XQ8043FN, chemically known as sulfanilamide, n(sup1)-amidino- but generally known as sulfaguanidine, which bears US NIH Compound Identifier 5324. European Medicines Agency schedules Sulfaguanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10703MIG.

UNSPSC 51283914 Sulfaguanidine is a Commodity code nominally covering a single pharmaceutical ingredient, but recent state and local activity under this code shows a significant mismatch — the opportunities solicited bear no relationship to sulfaguanidine itself. The code shows little relevant recent activity under its stated scope. The four recent opportunities posted under this code actually solicit naloxone and safe drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription program capabilities (Texas Health and Human Services Commission), medical and first aid supplies for emergency response (City of Tampa), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance, with Oregon participation). None of these solicitations target sulfaguanidine specifically, suggesting either a cataloging error in how the opportunities were tagged or a fundamental disconnect between the code's nominal scope and how state and local procurement offices are applying it.

The issuing bodies span state health agencies, counties, cities, and cooperative purchasing organizations — indicating fragmented acquisition across multiple jurisdiction types and governance models. Activity appears concentrated in the Southeast (Florida) and Upper Midwest (Minnesota, with regional extension to Oregon), with additional state-level procurement from Texas. The most concrete opportunity is the City of Tampa's IFB for medical and first aid supplies (due March 13, 2026, estimated contract value $700,000.00, with set-aside for certified Small Local Business Enterprises and a 5% SLBE discount capped at $10,000), followed by the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic pharmaceuticals and OTC products (due March 26, 2026, with awards effective July 1, 2026 through authorized wholesalers). Given the code's stated commodity definition and the actual work being bought, firms pursuing state and local business under this code should verify code applicability in each RFP or IFB before pursuing — the tag appears unreliable for procurement planning purposes.